Latest News | BIZ-STOCKS-AUROBINDO PHARMA  Aurobindo Pharma Shares Plunge over 6 Pc After USFDA Warning Letter for Subsidiary

New Delhi, Oct 22 (PTI) Shares of Aurobindo Pharma on Thursday tanked over 6 per cent after the company's step-down subsidiary received a warning letter from the US health regulator for its unit in New Jersey, US.

The stock declined 6.37 per cent to Rs 754 on the BSE.

Also Read | Jeff Goldblum Birthday: 7 Golden Movie Quotes of the Actor That Almost Seem Improvised.

On the NSE, it fell 6.53 per cent to Rs 753.50.

AuroLife Pharma, a wholly-owned step-down subsidiary of the company, has received a warning letter from the United States Food and Drug Administration (USFDA) for its oral solid manufacturing facility situated at Dayton, New Jersey, Aurobindo Pharma said in a BSE filing.

Also Read | Truecaller Introduces 'Call Reason', 'Schedule SMS' & 'SMS Translate' Features for Users: Report.

This follows the earlier letter dated June 4, 2020, issuing an OAI (Official Action Indicated) status for this facility.

Aurobindo Pharma said it believes the existing business from this facility will not be impacted.

"The company will be engaging with the regulator and is fully committed in resolving this issue at the earliest," it added.

The drug firm, however, did not provide any details of the contents of the warning letter.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)